Phase 2 Trial Comparing Two Versus Five MRI-Guided Stereotactic Ablative Radiotherapy Treatments for Prostate Cancer to Improve Sexual Quality of Life

What this Trial Is About

Researchers are evaluating a shorter course of ultra-hypofractionated radiotherapy UHRT for men with localized prostate cancer. This study compares a new two-treatment regimen to the standard five-treatment regimen, aiming to deliver an equivalent amount of radiation. UHRT is a promising approach that uses fewer but higher doses of radiation to target prostate cancer more effectively while potentially improving tolerability. The trial compares two groups one receiving two weekly fractions of 13.5 Gy each, and the other receiving five every-other-day fractions of 8 Gy each. Treatments use stereotactic ablative body radiotherapy SABR guided by MRI, which is a non-invasive, highly precise radiation technique. The two-treatment regimen is expected to be easier to tolerate and less invasive than other methods like high dose rate brachytherapy. Participants will be monitored closely from before treatment through five years after treatment. Researchers will assess changes in quality of life, treatment toxicity, prostate-specific antigen PSA levels, biochemical control of cancer, and need for additional therapy. Evaluations occur at multiple timepoints including weeks 1, 4, and 13, month 6, and every 6 months up to 5 years. This long-term follow-up helps measure treatment effects and patient well-being over time.

Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer